Safety by Design—Mitigating the Risk of Medication Errors Through Product Design

Siew,Adeline;

Safety by Design—Mitigating the Risk of Medication Errors Through Product Design

April 15, 2014

By Adeline Siew, PhD

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-04-15-2014

Volume 2014 eBook

Issue 1

Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.

The increasing prevalence and high cost of medication errors have prompted regulators and manufacturers to look into the role of product design in ensuring the safe and correct use of medicines. Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.

Download

Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook

Articles in this issue

Safety by Design—Mitigating the Risk of Medication Errors Through Product Design

Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators

Continuous Manufacturing for Solid-Dosage Drug Production

A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications

Using Modular Systems in Solid-Dosage Manufacturing

Advances in Hot-Melt Extrusion Manufacturing

Obtaining User-Defined Particle Size Distribution Using Dry Granulation

A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D

Selection of Excipients in Generic Formulations

Related Content

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

Susan Haigney

June 30th 2025

Article

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

3D Rendering of CAR - Chimeric Antigen Receptor Between T-Cell and Cancer Cell | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Patrick Lavery

June 26th 2025

Article

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.